Information Provided By:
Fly News Breaks for August 3, 2017
Aug 3, 2017 | 16:22 EDT
Oppenheimer analyst Mark Breidenbach initiated BioLineRx with a $3 price target saying its lead asset, BL-8040, could could unseat Sanofi's plerixafor as the preferred agent to combine with G-CSF for mobilizing stem cells in autologous hematopoietic stem cell transplants and said its Phase 3 GENESIS trial in the second half has a high probability of success.
News For BLRX From the Last 2 Days
There are no results for your query BLRX
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.